Genomenon and Agilent Partner to Improve Genomic Variant Interpretation
Summary
In the second phase of this project, a deeper integration using Mastermind’s API will allow Alissa Interpret users to evaluate and review the available literature search results in more detail directly in the application. “We are excited to partner with Agilent, an organization that is committed to making genomic analysis for clinical decision support faster, easier, and more effective,” said Mike Klein, CEO of Genomenon. “With this deeper integration, users of Agilent’s Alissa Interpret will experience an optimized workflow by being able to quickly view the evidence needed to make a genetic diagnosis.” “Leveraging Mastermind to enhance the unique collection of curated knowledge sources of Alissa Interpret strengthens our position in the somatic and hereditary disease markets,” said Kevin Meldrum, VP and GM of the Integrated Genomics Division at Agilent. As the world’s most comprehensive source for genomic literature in the variant interpretation space, Mastermind is used by over 2,000 diagnostic labs and integrated into 18 clinical-grade decision support platforms and reference databases across the globe. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision making and pharmaceutical drug discovery.
